Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Pain. 2020 Sep 1;161(9):2107–2118. doi: 10.1097/j.pain.0000000000001888

Fig. 3. Effects of S1PR2 and S1PR3 antagonists on OIH and antinociceptive tolerance.

Fig. 3.

Intrathecal administration of a selective S1PR2 (JTE-013; 2 nmol/day) or S1PR3 (CAY10444; 2 nmol/day) antagonist in male rats had no significant effects on the development of hyperalgesia (A; F(3,12)=6.1, p=0.0094, η2=0.60, n=4/group; 16 animals with no exclusions), but had modest, but significant, effects or tolerance (B; F(3,12)=84, p=2.6×10−8, η2=0.95, n=4/group; 16 animals with no exclusions) in rats. Results are mean±SD and analyzed by two-tailed, one-way ANOVA with Dunnett’s comparisons. *P<0.05 vs. Veh+Sal; †P<0.05 vs. Veh+Mor.